Rhenium-186-mercaptoacetyltriglycine-labeled Monoclonal Antibody for Radioimmunotherapy: In vitro Assessment, in vivo Kinetics and Dosimetry in Tumor-bearing Nude Mice (original) (raw)

Stability and immunoreactivity of 186 Re-labeled monoclonal antibody were examined, and its in vivo kinetics was investigated in tumor-bearing Balb/c nu/nu female mice to assess the feasibility of using it in radioimmunotherapy (RIT). A murine IgG 1 , A7, against a 45 kD glycoprotein in human colon cancer was radiolabeled with 186 Re by using a chelating method with a mercaptoacetyltriglycine (MAG3). 186 Re-MAG3 complex was conjugated to A7 after esterification of 186 Re-MAG3 with tetrafluorophenol (TFP). The efficiency of 186 Re-MAG3-TFP production and the labeling efficiency of A7 were 51-59% and 57-60%, respectively. Immunoreactivity of purified 186 Re-MAG3-A7 was 68.2% at infinite antigen excess. In 0.9% NaCl at 4°C, the radioactivity (12.7 MBq/mg, 3.55 MBq/ml) dissociated with time from 186 Re-MAG3-A7 as a small molecular weight moiety because of autoradiolysis. The addition of ascorbic acid, 5 mg/ml, as a radioprotectant or storage at − − − −80°C could effectively prevent the radiolysis of 186 Re-MAG3-A7 for 7 days. Immunoreactivity of 186 Re-MAG3-A7, 6.70 MBq/mg (6.66 MBq/ml), stored in the presence of ascorbic acid was well retained up to 8 days after the preparation. In colon cancer xenografted mice, 31.0% of the injected dose/g of 186 Re-MAG3-A7 had accumulated in the tumors at 24 h postinjection. Estimated radiation dose to tumors was 14.9 cGy/37 kBq up to 8 days postinjection which was 12-fold greater than the whole-body radiation dose. These in vivo characteristics were superior to those of A7 labeled with radioiodine, affording greater therapeutic ratios than 131 I-A7. Because of the better image quality of 186 Re-MAG3-A7 as well as more favorable dosimetry, 186 Re-MAG3-A7 would be a better choice for RIT of colon cancer than 131 I-A7. These results indicated the feasibility of RIT with 186 Re-MAG3-A7, though the prevention of radiolysis of the labeled antibody should be considered.